SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Buyout Binge Begins for Bio-Pharma, Diagnostics
EXAS
|
|
|
<> 
<>
<> With news late Friday that Roche (RHHBY) is prepared to up its bid for complete control of Genentech (DNA) to $95 from a previous offer of $89 per share and a $41M ($1.50 per share) all-stock takeover offer by Sequenom (SQNM) for EXACT Sciences (EXAS); 2009 is off to a strong start for M&A activity in the bio-pharma and diagnostic space.
Larger and well funded bio-pharma and diagnostic companies are opportunistically looking to expand their product offerings, pipeline prospects, patent portfolios, ...
|
A New Emerging Diagnostics Index
EXAS
|
|
|
<> 
The accompanying table [click to enlarge] includes 39 companies in the ETF Innovators [ETFI] Emerging Diagnostics Index of U.S.-listed stocks with market caps of $10-$200M. The index includes diabetes care device makers such as DexCom (DXCM), personalized medicine lab service providers such as Clarient (CLRT), clinical diagnostic test developers such as OraSure (OSUR), diagnostic imaging service providers such as Virtual Radiologic (VRAD), diagnostic equipment makers such as Vision Sciences (VSCI), and genetic analysis + molecu...
|
Bullish on EXAS ...
EXAS
|
|
|
EXACT Sciences Corporation, an applied genomics company, develops proprietary DNA-based technologies for use in the detection of cancer. The company licenses its technologies for use in commercial testing services, and marketed under the PreGen-Plus name. PreGen-Plus is a non-invasive stool-based DNA testing service for the detection of colorectal cancer. It has a strategic alliance with LabCorp to commercialize PreGen-Plus. EXACT Sciences Corporation was founded in 1995 and is headquartered in Marlborough, Massachusetts.
|
EXACT Sciences Next Generation Stool-Based DNA Technology Outperforms Blood Plasma Testing
EXAS
|
|
|
EXACT Sciences (EXAS) announced the published results of a study in which stool and blood plasma were compared head-to-head for the detection of colorectal cancer [CRC] using an improved BEAMing DNA detection technology from Johns Hopkins University. Study results demonstrated 92% sensitivity for detecting CRC in stool samples, which outperformed blood plasma testing -- especially in the detection of early stage disease.
In the study, a total of 25 stool DNA [sDNA] samples from colorectal cancer patients were analyzed and a next generation sDNA technology correctly identified 23 (92%...
|
ColoSure & Cost Reductions Key to EXACT's Future
EXAS
|
|
|
 EXACT Sciences (EXAS) recently announced plans to implement a cost reduction strategy, which includes suspending a clinical validation study of its V2 DNA-based colorectal cancer [CRC] screening technology, eliminating eight jobs, and renegotiating fixed commitments. The Company expects these initiatives will fund operations through at least 2Q09 based on current liquidity, without the need to raise capital at currently depressed market prices for the stock. EXACT's partner LabCorp (LH) has recently launched a single-marker, lab-based fecal DNA test (based on the Vimentin gene which ...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on EXAS |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About EXACT Sciences Corp.
- Answers.com
